[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Yang JY, Walicki J, Abderrahmani A, Cornu M, Waeber G, Thorens B, Widmann C: Expression of an uncleavable N-terminal RasGAP fragment in insulin-secreting cells increases their resistance toward apoptotic stimuli without affecting their glucose-induced insulin secretion. J Biol Chem; 2005 Sep 23;280(38):32835-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis of pancreatic beta cells is implicated in the onset of type 1 and type 2 diabetes.
  • Consequently, strategies aimed at increasing the resistance of beta cells toward apoptosis could be beneficial in the treatment of diabetes.
  • Here we demonstrate that an uncleavable form of fragment N activates Akt, represses NF-kappaB activity, and protects the conditionally immortalized pancreatic insulinoma betaTC-tet cell line against various insults, including exposure to genotoxins, trophic support withdrawal, and incubation with inflammatory cytokines.
  • The pathways regulated by fragment N are therefore promising targets for antidiabetogenic therapy.
  • [MeSH-minor] Animals. Caspase 3. Caspases / metabolism. Cell Line. Cisplatin / pharmacology. Cross-Linking Reagents / pharmacology. Cytokines / metabolism. Dose-Response Relationship, Drug. Humans. Immunohistochemistry. Inflammation. Insulinoma / metabolism. Lentivirus / genetics. Mice. Microscopy, Fluorescence. NF-kappa B / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Plasmids / metabolism. Protein Binding. Protein Structure, Tertiary. Rats. Rats, Wistar. Time Factors

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046410.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Cytokines; 0 / Insulin; 0 / NF-kappa B; 0 / ras GTPase-Activating Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; IY9XDZ35W2 / Glucose; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Luo LG, Jackson I: Thyrotropin releasing hormone (TRH) may preserve pancreatic islet cell function: potential role in the treatment of diabetes mellitus. Acta Biomed; 2007;78 Suppl 1:216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyrotropin releasing hormone (TRH) may preserve pancreatic islet cell function: potential role in the treatment of diabetes mellitus.
  • The significance of this association is emphasised by the report that the TRH knock-out (KO) mouse is hyperglycemic.
  • These studies point to a potential therapeutic role for TRH in the treatment of DM in man.
  • [MeSH-major] Diabetes Mellitus / drug therapy. Islets of Langerhans / drug effects. Thyrotropin-Releasing Hormone / physiology
  • [MeSH-minor] Animals. Blood Glucose / metabolism. Cell Line, Tumor / metabolism. Diabetes Mellitus, Experimental / drug therapy. Drug Evaluation, Preclinical. Forecasting. Gene Expression Regulation. Homeostasis. Humans. Hyperglycemia / drug therapy. Insulin / secretion. Insulinoma / metabolism. Insulinoma / pathology. Mice. Mice, Knockout. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Rabbits. Rats. Stem Cells / drug effects. Streptozocin

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465334.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 5W494URQ81 / Streptozocin; 5Y5F15120W / Thyrotropin-Releasing Hormone
  •  go-up   go-down


3. Kimple ME, Joseph JW, Bailey CL, Fueger PT, Hendry IA, Newgard CB, Casey PJ: Galphaz negatively regulates insulin secretion and glucose clearance. J Biol Chem; 2008 Feb 22;283(8):4560-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clues to one potential function recently emerged with the finding that activation of Galphaz inhibits glucose-stimulated insulin secretion in an insulinoma cell line (Kimple, M.
  • To extend this study in vivo, a Galphaz knock-out mouse model was utilized to determine whether Galphaz function plays a role in the inhibition of insulin secretion.
  • No differences were discovered in the gross morphology of the pancreatic islets or in the islet DNA, protein, or insulin content between Galphaz-null and wild-type mice.
  • There was also no difference between the insulin sensitivity of Galphaz-null mice and wild-type controls, as measured by insulin tolerance tests.
  • Galphaz-null mice did, however, display increased plasma insulin concentrations and a corresponding increase in glucose clearance following intraperitoneal and oral glucose challenge as compared with wild-type controls.
  • The increased plasma insulin observed in Galphaz-null mice is most likely a direct result of enhanced insulin secretion, since pancreatic islets isolated from Galphaz-null mice exhibited significantly higher glucose-stimulated insulin secretion than those of wild-type mice.
  • These findings indicate that Galphaz may be a potential new target for therapeutics aimed at ameliorating beta-cell dysfunction in Type 2 diabetes.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096703.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM55717; United States / NIDDK NIH HHS / DK / K01 DK080845; United States / NIDDK NIH HHS / DK / F32 DK067799; United States / NIDDK NIH HHS / DK / DK67799; United States / NIDDK NIH HHS / DK / DK42583
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GTP-Binding Protein alpha Subunits; 0 / Insulin; 0 / Sweetening Agents; E0399OZS9N / Cyclic AMP; EC 4.6.1.1 / Adenylyl Cyclases; IY9XDZ35W2 / Glucose
  •  go-up   go-down


Advertisement
4. Bara H, Thulé PM, Sambanis A: A cell-based approach for diabetes treatment using engineered non-beta cells. J Diabetes Sci Technol; 2009 May 01;3(3):555-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cell-based approach for diabetes treatment using engineered non-beta cells.
  • To overcome the limitations of tissue availability and recipient immunosuppression, encapsulation of nonautologous cells and use of potentially autologous nonislet cells, the latter engineered for insulin secretion, are being pursued.
  • This article reports on recent findings with the implantation of tissue constructs containing enteroendocrine cells stably expressing recombinant insulin in diabetic mice.
  • METHODS: Mouse GLUTag-INS cells engineered to secrete human insulin were developed and incorporated in tissue constructs as reported previously.
  • Constructs were implanted intraperitoneally in diabetic mice, and blood glucose levels, animal weights, and plasma insulin levels were measured at various time points.
  • RESULTS: GLUTag-INS-containing tissue constructs secreted insulin preimplantation and postexplantation, and human insulin was detected in the plasma of diabetic mice.
  • CONCLUSIONS: A variety of cell types and of encapsulation methods to enhance immune acceptance of insulin-secreting grafts are being pursued.
  • [MeSH-major] Bioengineering. Cell- and Tissue-Based Therapy / methods. Diabetes Mellitus, Experimental / therapy. Enteroendocrine Cells / metabolism. Enteroendocrine Cells / transplantation. Insulin / metabolism
  • [MeSH-minor] Animals. Blood Glucose / metabolism. Cell Transplantation. Disease Models, Animal. Humans. Insulinoma / pathology. Mice. Mice, Inbred C57BL. Pancreatic Neoplasms / pathology. Streptozocin

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Diabetes Technology Society.
  • [Cites] Gene Ther. 2000 Feb;7(3):205-14 [10694797.001]
  • [Cites] Hum Gene Ther. 2003 Oct 10;14(15):1401-13 [14577921.001]
  • [Cites] Gene Ther. 2000 Oct;7(20):1744-52 [11083496.001]
  • [Cites] Science. 2000 Dec 8;290(5498):1959-62 [11110661.001]
  • [Cites] J Nutr. 2001 Mar;131(3):709-12 [11238747.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20636-42 [15014073.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):977-86 [8366922.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6241-5 [8119968.001]
  • [Cites] Eur J Immunol. 1994 Aug;24(8):1853-7 [8056042.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 5;206(1):279-86 [7818532.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):92-103 [8550855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8595-600 [8710916.001]
  • [Cites] Diabetes. 1998 Jan;47(1):5-12 [9421368.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2610-9 [15731364.001]
  • [Cites] Curr Mol Med. 2006 Jun;6(4):369-74 [16900660.001]
  • [Cites] J Transl Med. 2007;5:1 [17201925.001]
  • [Cites] Exp Physiol. 2007 Jan;92(1):241-9 [17068109.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Jan 14;60(2):106-13 [18053613.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 20;371(1):39-43 [18406351.001]
  • [Cites] Autoimmun Rev. 2008 Jul;7(7):550-7 [18625444.001]
  • [Cites] Diabetes Metab. 2008 Feb;34 Suppl 2:S73-7 [18640589.001]
  • [Cites] Biotechnol Bioeng. 2009 Jul 1;103(4):828-34 [19280668.001]
  • [Cites] Curr Pharm Des. 2001 Sep;7(14):1399-412 [11472275.001]
  • [Cites] FEBS Lett. 2003 Feb 27;537(1-3):193-7 [12606056.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 4;303(2):645-52 [12659868.001]
  • [Cites] Transfus Med Rev. 2003 Apr;17(2):95-109 [12733103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8384-8 [12815107.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):230-8 [10911004.001]
  • (PMID = 20144295.001).
  • [ISSN] 1932-2968
  • [Journal-full-title] Journal of diabetes science and technology
  • [ISO-abbreviation] J Diabetes Sci Technol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK076801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 5W494URQ81 / Streptozocin
  • [Other-IDs] NLM/ PMC2769879
  •  go-up   go-down


5. Lee M, Han SO, Ko KS, Koh JJ, Park JS, Yoon JW, Kim SW: Repression of GAD autoantigen expression in pancreas beta-Cells by delivery of antisense plasmid/PEG-g-PLL complex. Mol Ther; 2001 Oct;4(4):339-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also transfected pRIP-AS-GAD/PEG-g-PLL complex into a GAD-producing mouse insulinoma (MIN6) cell line.
  • [MeSH-major] Autoantigens / biosynthesis. DNA, Antisense / therapeutic use. Gene Expression Regulation, Enzymologic. Glutamate Decarboxylase / biosynthesis. Islets of Langerhans / metabolism. Polyethylene Glycols / metabolism. Polylysine / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Drug Carriers / metabolism. Injections, Intravenous. Insulinoma / genetics. Insulinoma / metabolism. Male. Mice. Organ Specificity. Plasmids / administration & dosage. Plasmids / genetics. Plasmids / therapeutic use. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection / methods. Tumor Cells, Cultured. beta-Galactosidase / genetics. beta-Galactosidase / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11592837.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK51689
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / DNA, Antisense; 0 / Drug Carriers; 0 / RNA, Messenger; 25104-18-1 / Polylysine; 30IQX730WE / Polyethylene Glycols; EC 3.2.1.23 / beta-Galactosidase; EC 4.1.1.15 / Glutamate Decarboxylase
  •  go-up   go-down


6. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G: [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res; 2007 Jun 15;13(12):3696-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
  • PURPOSE: Although metabolic changes make diagnosis of insulinoma relatively easy, surgical removal is hampered by difficulties in locating it, and there is no efficient treatment for malignant insulinoma.
  • We have previously shown that the high density of glucagon-like peptide-1 receptors (GLP-1R) in human insulinoma cells provides an attractive target for molecular imaging and internal radiotherapy.
  • In this study, we investigated the therapeutic potential of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4, an (111)In-labeled agonist of GLP-1, in a transgenic mouse model of human insulinoma.
  • EXPERIMENTAL DESIGN: [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4 was assessed in the Rip1Tag2 mouse model of pancreatic beta-cell carcinogenesis, which exhibits a GLP-1R expression comparable with human insulinoma.
  • Tumor uptake and response, the mechanism of action of the radiopeptide, and therapy toxicity were investigated.
  • RESULTS: Tumor uptake was >200% injected activity per gram, with a dose deposition of 3 Gy/MBq at 40 pmol [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4.
  • Other GLP-1R-positive organs showed > or =30 times lower dose deposition.
  • The therapeutic effect was due to increased tumor cell apoptosis and necrosis and decreased proliferation.
  • CONCLUSIONS: The results suggest that [Lys(40)(Ahx-DTPA-(111)In)NH(2)]-Exendin-4 is a promising radiopeptide capable of selectively targeting insulinoma.
  • Furthermore, Auger-emitting radiopharmaceuticals such as (111)In are able to produce a marked therapeutic effect if a high tumor uptake is achieved.
  • [MeSH-major] Indium Radioisotopes / therapeutic use. Insulinoma / radionuclide imaging. Organometallic Compounds / therapeutic use. Pancreatic Neoplasms / radionuclide imaging. Peptides / therapeutic use. Radiopharmaceuticals / therapeutic use. Receptors, Glucagon / metabolism
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Female. Glucagon-Like Peptide-1 Receptor. Male. Mice. Mice, Transgenic. Pentetic Acid / pharmacokinetics. Pentetic Acid / therapeutic use. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575235.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (Lys(40)(Ahx-DTPA-111In)NH2)exendin-14; 0 / GLP1R protein, human; 0 / Glp1r protein, mouse; 0 / Glucagon-Like Peptide-1 Receptor; 0 / Indium Radioisotopes; 0 / Organometallic Compounds; 0 / Peptides; 0 / Radiopharmaceuticals; 0 / Receptors, Glucagon; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


7. Mziaut H, Kersting S, Knoch KP, Fan WH, Trajkovski M, Erdmann K, Bergert H, Ehehalt F, Saeger HD, Solimena M: ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci U S A; 2008 Jan 15;105(2):674-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now show that knockdown of ICA512 decreases cyclin D1 levels and proliferation of insulinoma INS-1 cells, whereas beta-cell regeneration is reduced in partially pancreatectomized ICA512-/- mice.
  • These results identify ICA512 as a regulator of cyclins D and beta-cell proliferation through STATs and may have implication for diabetes therapy.
  • [MeSH-minor] Animals. Cell Proliferation. Cyclin D. Cyclin D2. Diabetes Mellitus / drug therapy. Diabetes Mellitus / metabolism. Humans. Insulin / metabolism. Models, Biological. Phosphorylation. Rats. Regeneration. Signal Transduction


8. Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol; 2009 Jan;104(1):171-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many well-differentiated endocrine carcinomas show rather low rates of tumor growth, more than two-thirds of pancreatic endocrine carcinomas display distant metastases at the time of diagnosis.
  • As the currently applied therapies beyond surgery only achieve partial or complete response rates of approximately 15%, additional chemotherapeutic targets are needed, especially in the therapy of inoperable and progressive pancreatic endocrine carcinomas.
  • Functional tests were performed using the human pancreas carcinoid cell line BON and the mouse insulinoma cell line beta-TC-3.
  • The treatment of the human pancreas carcinoid cell line BON and the mouse insulinoma cell line beta-TC-3 with EGFR and COX-2 inhibitors (monotherapy and combined therapy) resulted in a significant, dose-dependent reduction of cell viability coupled with increased apoptosis.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Pancreatic Neoplasms / metabolism. Pyrazoles / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Sulfonamides / therapeutic use. Tyrphostins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Apoptosis / drug effects. Blotting, Western. Carcinoid Tumor / metabolism. Celecoxib. Cell Line, Tumor. Cell Survival / drug effects. Cyclooxygenase 2 Inhibitors / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Insulinoma / metabolism. Male. Mice. Mice, Transgenic. Middle Aged. Quinazolines. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098866.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; 0 / Tyrphostins; 170449-18-0 / tyrphostin AG 1478; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


9. Yamada C, Nagashima K, Takahashi A, Ueno H, Kawasaki Y, Yamada Y, Seino Y, Inagaki N: Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol; 2006 Dec 28;553(1-3):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gatifloxacin-induced hypoglycemia is associated with concomitant use of sulfonylureas, and usually occurs immediately after administration of the drug.
  • We find that gatifloxacin acutely stimulates insulin secretion from mouse pancreatic islets and that glibenclamide has additive effects on gatifloxacin-induced insulin secretion.
  • We also demonstrate that chronic gatifloxacin treatment decreases islet insulin content by inhibiting insulin biosynthesis, which process may be associated with gatifloxacin-induced hyperglycemia.
  • Because the risk of potentially life-threatening dysglycemia is increased during gatifloxacin therapy, these findings have important implications for clinical practice.
  • [MeSH-minor] Animals. Blood Glucose / metabolism. Cell Line, Tumor. Cell Separation. Glyburide / pharmacology. Hypoglycemic Agents / pharmacology. In Vitro Techniques. Insulinoma / metabolism. Islets of Langerhans / drug effects. Islets of Langerhans / secretion. Male. Mice. Mice, Inbred C57BL. Pancreatic Neoplasms / metabolism. Quinolones / pharmacology. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070519.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Blood Glucose; 0 / Fluoroquinolones; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin Antagonists; 0 / Quinolones; 0 / RNA, Messenger; L4618BD7KJ / gatifloxacin; SX6K58TVWC / Glyburide
  •  go-up   go-down


10. Nakamura A, Terauchi Y, Ohyama S, Kubota J, Shimazaki H, Nambu T, Takamoto I, Kubota N, Eiki J, Yoshioka N, Kadowaki T, Koike T: Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. Endocrinology; 2009 Mar;150(3):1147-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed four mouse groups: wild-type mice and beta-cell-specific haploinsufficiency of glucokinase gene (Gck(+/-)) mice on a high-fat (HF) diet.
  • Rodent insulinoma cells and isolated islets were used to evaluate beta-cell proliferation by GKA.
  • Glucose tolerance was improved shortly after the GKA treatment in both genotypes of mice. beta-Cell mass increased in wild-type mice compared with Gck(+/-) mice, but a further increase was not observed after the administration of GKA in both genotypes.
  • Interestingly, GKA was able to up-regulate insulin receptor substrate-2 (Irs-2) expression in insulinoma cells and isolated islets.
  • The administration of GKA increased 5-bromo-2-deoxyuridine (BrdU) incorporation in insulinoma cells, and 3 d administration of GKA markedly increased BrdU incorporation in mice treated with GKA in both genotypes, compared with those without GKA.
  • This apparent discrepancy can be explained by a chronic reduction in ambient blood glucose levels by GKA treatment.
  • [MeSH-minor] Animals. Body Weight / drug effects. Bromodeoxyuridine / pharmacokinetics. Cells, Cultured. Diet, Atherogenic. Dietary Fats / pharmacology. Drug Evaluation, Preclinical. Enzyme Activation / drug effects. Enzyme Activation / physiology. Glucose Intolerance / drug therapy. Insulin / secretion. Insulin Receptor Substrate Proteins / genetics. Insulin Receptor Substrate Proteins / metabolism. Mice. Mice, Transgenic. Organ Size / drug effects

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008318.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin Receptor Substrate Proteins; 0 / Irs2 protein, rat; EC 2.7.1.2 / Glucokinase; G34N38R2N1 / Bromodeoxyuridine; IY9XDZ35W2 / Glucose
  •  go-up   go-down


11. Codd EE, Baker J, Brandt MR, Bryant S, Cai C, Carson JR, Chevalier KM, Colburn RW, Coogan TP, Dax SL, Decorte B, Kemmerer M, Legrand EK, Lenhard JM, Leone AM, Lin L, Mabus JR, McDonnell ME, McMillian MK, McNally JJ, Stone DJ Jr, Wang CY, Zhang SP, Flores CM: Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine. Toxicol Sci; 2010 Oct;117(2):493-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A review of the literature on the antiserotonergic and antihistaminergic drug cyproheptadine (CPH) and its metabolites revealed shared structural features as well as similar hyperglycemic effects to the present series of DOR agonists.
  • Furthermore, the RINm5F cell insulin results correlated with the diabetogenic effect of the compounds in a 5-day mouse study.
  • [MeSH-major] Cyproheptadine / toxicity. Hyperglycemia / chemically induced. Insulin-Secreting Cells / drug effects. Narcotic Antagonists / toxicity. Pancreas / drug effects. Serotonin Antagonists / toxicity
  • [MeSH-minor] Animals. Blood Glucose / analysis. Blood Glucose / drug effects. Cell Enlargement / drug effects. Cell Line, Tumor. Diabetes Mellitus, Type 1 / metabolism. Dogs. Epiphyses / abnormalities. Epiphyses / metabolism. Female. High-Throughput Screening Assays. Insulin / blood. Insulinoma / drug therapy. Insulinoma / metabolism. Male. Mice. Osteochondrodysplasias / metabolism. Rats. Rats, Sprague-Dawley. Vacuoles / drug effects. Vacuoles / ultrastructure

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • Hazardous Substances Data Bank. CYPROHEPTADINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20616206.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Narcotic Antagonists; 0 / Serotonin Antagonists; 2YHB6175DO / Cyproheptadine; Wolcott-Rallison syndrome
  •  go-up   go-down


12. Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH, Kim SW: Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release; 2005 Oct 20;107(3):562-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PEI-PEG-Fab' showed about 10-fold higher transfection efficiency (relative luciferase activity) than PEI-PEG in GAD-expressing mouse insulinoma cells (MIN6), however the transfection efficiency of PEI-PEG-Fab' reduced to that of PEI-PEG in GAD negative cells (293) and in the presence of competitive free Fab'.
  • Considering the neutral surface charge of its complexes with DNA, and selectivity toward the islet cells expressing a specific antigen, the PEI-PEG-Fab' conjugate could be thought as a potential candidate of the systemic gene therapy for the treatment of type I diabetes.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / immunology. Drug Delivery Systems. Genetic Therapy / methods. Glutamate Decarboxylase / immunology. Insulin-Secreting Cells / drug effects. Insulin-Secreting Cells / immunology
  • [MeSH-minor] Animals. Cell Survival / drug effects. Electrophoresis, Agar Gel. Immunoglobulin Fab Fragments / genetics. Mice. Microscopy, Confocal. Polyethylene Glycols. Polyethyleneimine. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139384.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fab Fragments; 30IQX730WE / Polyethylene Glycols; 9002-98-6 / Polyethyleneimine; EC 4.1.1.15 / Glutamate Decarboxylase
  •  go-up   go-down


13. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, Duarte A: Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer; 2010 Nov 23;10:641
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
  • This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in combination, in reducing the growth of an autochthonous mouse tumor and assesses potential adverse effects.
  • RESULTS: Dll4 allele deletion or soluble Dll4 treatment resulted in increased tumor vessel density, reduced mural cell recruitment and vessel perfusion which resulted in reduced tumor size.
  • Induced endothelial specific Dll4 loss-of-function caused hepatic vascular alterations, which were prevented by concomitant sEphB4-Alb treatment.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2474-8 [15466159.001]
  • [Cites] Curr Opin Neurobiol. 2004 Jun;14(3):379-83 [15194119.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):70-4 [7596437.001]
  • [Cites] Genes Dev. 1999 Feb 1;13(3):295-306 [9990854.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15949-54 [15520367.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2730-5 [15545631.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8690-7 [16204037.001]
  • [Cites] Cell. 2006 Jan 13;124(1):161-73 [16413489.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 17;341(3):708-14 [16430858.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2330-8 [16322467.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8501-10 [16951162.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1032-7 [17183313.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1083-7 [17183323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24 [17296940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3225-30 [17296941.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4753-60 [17311993.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] J Thromb Haemost. 2009 Jan;7(1):21-33 [18983480.001]
  • [Cites] Blood. 2009 Jan 1;113(1):254-63 [18836096.001]
  • [Cites] Circ Res. 2009 Feb 27;104(4):466-75 [19150886.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3631-9 [19218547.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23436-43 [19564336.001]
  • [Cites] Blood. 2010 Jan 28;115(4):887-95 [19965636.001]
  • [Cites] Nature. 2010 Feb 11;463(7282):E6-7 [20147986.001]
  • [Cites] Nature. 2010 May 27;465(7297):487-91 [20445540.001]
  • [Cites] Nature. 2010 May 27;465(7297):483-6 [20445537.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1464-8 [11245452.001]
  • [Cites] Differentiation. 2001 Dec;69(2-3):135-44 [11798067.001]
  • [Cites] Development. 2002 Mar;129(6):1397-410 [11880349.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Annu Rev Neurosci. 2003;26:565-97 [12730322.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1142-51 [14561699.001]
  • [Cites] Recent Prog Horm Res. 2004;59:51-71 [14749497.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • (PMID = 21092311.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 079218-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / DLL4 protein, mouse; 0 / Ephrin-B2; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Receptors, Notch; 0 / Recombinant Fusion Proteins; EC 2.7.1.- / Ephb4 protein, mouse; EC 2.7.10.1 / Receptor, EphB4
  • [Other-IDs] NLM/ PMC3001720
  •  go-up   go-down


14. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest; 2006 Oct;116(10):2610-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little is known about the reversibility of these changes after treatment ends.
  • One day after drug withdrawal, endothelial sprouts grew into empty sleeves of basement membrane.
  • Importantly, the regrown vasculature regressed as much during a second treatment as it did in the first.
  • Inhibition of MMPs or targeting of type IV collagen cryptic sites by antibody HUIV26 did not eliminate the sleeves or slow revascularization.
  • These results suggest that empty sleeves of basement membrane and accompanying pericytes provide a scaffold for rapid revascularization of tumors after removal of anti-VEGF therapy and highlight their importance as potential targets in cancer therapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2003 Nov;163(5):1801-15 [14578181.001]
  • [Cites] Circ Res. 2004 Apr 16;94(7):984-92 [15001532.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):35-52 [15215160.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6137-43 [15342397.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] J Cell Biol. 1972 Nov;55(2):406-19 [5076781.001]
  • [Cites] Brain Res. 1983 Dec 12;288(1-2):61-75 [6661636.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Cell Tissue Res. 1992 Dec;270(3):469-74 [1283113.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):372-82 [8311120.001]
  • [Cites] Nature. 1994 Feb 10;367(6463):576-9 [8107827.001]
  • [Cites] Exp Neurol. 1994 Aug;128(2):216-25 [8076665.001]
  • [Cites] Lab Invest. 1995 Nov;73(5):658-66 [7474939.001]
  • [Cites] Biosci Biotechnol Biochem. 1996 May;60(5):856-61 [8704315.001]
  • [Cites] Brain Res. 1996 Dec 2;742(1-2):265-70 [9117404.001]
  • [Cites] J Anat. 1997 Jan;190 ( Pt 1):57-71 [9034882.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7151-8 [9054410.001]
  • [Cites] FASEB J. 1997 Apr;11(5):365-73 [9141503.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Brain Res. 1998 May 11;792(2):309-18 [9593961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8795-800 [9671758.001]
  • [Cites] Cancer Metastasis Rev. 1998 Jun;17(2):155-61 [9770111.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):845-54 [10213221.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:236-70 [10415735.001]
  • [Cites] Nat Neurosci. 2002 Sep;5(9):861-7 [12172551.001]
  • [Cites] Nat Neurosci. 2002 Sep;5(9):821-2 [12196804.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4152-60 [10945623.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):30-6 [11150434.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4015-22 [12124335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3226-31 [12374693.001]
  • [Cites] J Clin Invest. 2002 Dec;110(11):1619-28 [12464667.001]
  • [Cites] Angiogenesis. 2002;5(1-2):35-44 [12549858.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1163-77 [12810700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7785-90 [12805568.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Aug;21(2):185-92 [10423400.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):450-62 [15563309.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59 [16172161.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76 [16172168.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Curr Opin Hematol. 2006 May;13(3):175-81 [16567962.001]
  • [Cites] Am J Pathol. 2006 May;168(5):1576-86 [16651624.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):348-64 [16713103.001]
  • [CommentIn] J Clin Invest. 2006 Oct;116(10):2585-7 [17016553.001]
  • (PMID = 17016557.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NCI NIH HHS / CA / R01 CA082923; United States / NCI NIH HHS / CA / P50-CA90270; United States / NCI NIH HHS / CA / P50 CA090270; United States / NHLBI NIH HHS / HL / R01 HL059157; United States / NCI NIH HHS / CA / CA082923; United States / NHLBI NIH HHS / HL / HL-59157
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antigens, CD31; 0 / Collagen Type IV; 0 / Imidazoles; 0 / Indazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / Organic Chemicals; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 10T6626FRK / prinomastat; C9LVQ0YUXG / axitinib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC1578604
  •  go-up   go-down


15. Abe M, Toyohara T, Ishii A, Suzuki T, Noguchi N, Akiyama Y, Shiwaku HO, Nakagomi-Hagihara R, Zheng G, Shibata E, Souma T, Shindo T, Shima H, Takeuchi Y, Mishima E, Tanemoto M, Terasaki T, Onogawa T, Unno M, Ito S, Takasawa S, Abe T: The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides. Drug Metab Pharmacokinet; 2010;25(3):274-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rat oatp1/slco1a1, oatp2/slco1a4 and oatp3/slco1a5 were expressed in the pancreas, and rat oatp3/slco1a5 was also detected in rat insulinoma cell line INS-1e.
  • [MeSH-minor] Adiponectin / blood. Animals. Biological Transport / drug effects. Cell Line, Tumor. Diabetes Mellitus / drug therapy. Hydroxymethylglutaryl CoA Reductases. Immunohistochemistry. Male. Mice. Mice, Inbred Strains. Models, Animal. Pancreas / cytology. Pancreas / drug effects. Rats. Rifampin / pharmacology. Sulfobromophthalein / pharmacology

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. SODIUM SULFOBROMOPHTHALEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610886.001).
  • [ISSN] 1880-0920
  • [Journal-full-title] Drug metabolism and pharmacokinetics
  • [ISO-abbreviation] Drug Metab. Pharmacokinet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Adipoq protein, mouse; 0 / Insulin; 0 / Organic Anion Transporters, Sodium-Independent; 0C2P5QKL36 / Sulfobromophthalein; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; KXO2KT9N0G / Pravastatin; VJT6J7R4TR / Rifampin
  •  go-up   go-down


16. Størling J, Allaman-Pillet N, Karlsen AE, Billestrup N, Bonny C, Mandrup-Poulsen T: Antitumorigenic effect of proteasome inhibitors on insulinoma cells. Endocrinology; 2005 Apr;146(4):1718-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumorigenic effect of proteasome inhibitors on insulinoma cells.
  • Malignant insulinoma is a critical cancer form with a poor prognosis.
  • Because cure by surgery is infrequent, effective chemotherapy is in demand.
  • Induction of cell death in tumor cells by proteasome inhibitors is emerging as a potential strategy in cancer therapy.
  • Here we investigated whether inhibition of the proteasome has an antitumorigenic potential in insulinoma cells.
  • Exposure of mouse betaTC3 insulinoma cells to the proteasome inhibitor N-Acetyl-Leu-Leu-Nle-CHO (ALLN) reduced cell viability, activated caspase-3, induced apoptosis, and suppressed insulin release.
  • Treatment with ALLN also resulted in phosphorylation of c-jun N-terminal kinase (JNK) and an increase in in vitro phosphorylation of c-jun.
  • In insulinoma cells with impaired JNK signaling, ALLN-induced apoptosis was significantly suppressed.
  • Our findings demonstrate that proteasome inhibitors possess antitumorigenic and antiinsulinogenic effects on insulinoma cells.
  • [MeSH-major] Acetylcysteine / analogs & derivatives. Antineoplastic Agents / pharmacology. Cysteine Proteinase Inhibitors / pharmacology. Insulinoma / drug therapy. Pancreatic Neoplasms / drug therapy. Proteasome Inhibitors
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / antagonists & inhibitors. Animals. Apoptosis / drug effects. Binding Sites. Cell Line, Tumor. JNK Mitogen-Activated Protein Kinases / metabolism. Leupeptins / pharmacology. Mice. Rats. Signal Transduction / drug effects. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15618349.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Leupeptins; 0 / Mapk8ip protein, mouse; 0 / Proteasome Inhibitors; 0 / Tumor Suppressor Protein p53; 110044-82-1 / acetylleucyl-leucyl-norleucinal; 133343-34-7 / lactacystin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


17. Huang L, Yan M, Kirschke CP: Over-expression of ZnT7 increases insulin synthesis and secretion in pancreatic beta-cells by promoting insulin gene transcription. Exp Cell Res; 2010 Oct 1;316(16):2630-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we demonstrated that zinc transporter 7 (ZnT7, Slc30a7) was co-expressed with insulin in the islet of Langerhans in the mouse pancreas.
  • In RIN5mF cells (rat insulinoma cells), ZnT7 was found mainly residing in the perinuclear region of the cell, which is consistent with its Golgi apparatus localization.
  • [MeSH-major] Cation Transport Proteins / metabolism. Glucose / pharmacology. Insulin / genetics. Insulin / secretion. Insulin-Secreting Cells / metabolism. Transcription, Genetic / drug effects
  • [MeSH-minor] Animals. Blotting, Western. Cells, Cultured. Electrophoretic Mobility Shift Assay. Fluorescent Antibody Technique. Immunoprecipitation. Insulinoma / drug therapy. Insulinoma / metabolism. Insulinoma / pathology. Islets of Langerhans / cytology. Islets of Langerhans / metabolism. Male. Mice. Mice, Inbred C57BL. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20599947.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 0 / Insulin; 0 / RNA, Messenger; 0 / ZnT7 protein, mouse; IY9XDZ35W2 / Glucose
  •  go-up   go-down






Advertisement